•  

Posts Tagged: Qiagen N.V.

Xagenic announces $15 million financing round with Series B investors

TORONTO (July 9, 2015) — Xagenic, a molecular diagnostics company developing the lab-free Xagenic X1™ platform for point-of-care use, today announced that it has raised $15 million (CAD). Each of the company's Series B investors has participated in this financing, including Domain Associates, CTI Life Sciences, BDC Capital and the Ontario Capital Growth Corporation. PE Hub, Cantech Letter, Genome Web, Fierce Medical Devices and the Wall Street Journal's Venture Capital Dispatch blog covered this announcement. In June, Xagenic also announced it has acquired ... Read more

Dr. Hofstein’s Op-Ed for The Hill-Times, “Biotechnology research: A knowledge economy”

This op-ed on Canadian biotechnology and the knowledge economy appeared in The Hill-Times (subscription required), Canada's politics and government newsweekly, September 9: Obesity, cancer, heart disease and stroke, diabetes, Parkinson’s disease, Alzheimer’s, or the more general stresses of an aging population: no matter which area of concern holds our collective gaze from moment to moment, improving health outcomes and healthcare is the No. 1 challenge for the world’s economy. Canada has the holistic approach and translational research necessary to address health care’s pervasive ... Read more

FedDev Ontario awards Xagenic Inc. $990,000 through Investing in Business Innovation initiative

TORONTO, Feb. 19, 2013 — Xagenic Inc., a privately-held molecular diagnostics company, today announced that it will receive up to $990,000 in funding from the Government of Canada to support design and development of the first lab-free molecular diagnostic platform with a 20-minute time to result. The Honourable Gary Goodyear, Minister of State for the Federal Economic Development Agency for Southern Ontario (FedDev Ontario), made the announcement in the keynote speech at the Conference Board of Canada's Business Innovation Summit 2013 ... Read more

BioCentury Features Xagenic’s PCR-Based Infection-Diagnosis Technology

Xagenic, a MaRS Innovation spin-off company, was featured in the most recent issue of BioCentury. Here's an excerpt (the article only available to BioCentury subscribers): PCR-based diagnosis of infections can delay treatment decisions by days or hours because the method relies on technical expertise and equipment not available in most point-of-care settings. Xagenic Inc.'s chip-based arrays use a non-PCR, electrochemical approach to diagnose bacterial infections at the point of care in 20 minutes with PCR-like accuracy. Xagenic's core technology is a silicon chip containing ... Read more

Xagenic Raises $10 million in Series A Financing

TORONTO (January 30, 2012) – Xagenic Inc., a start-up company created by Dr. Shana Kelley, in partnership with MaRS Innovation, today reached a significant milestone by successfully completing series A financing totaling $10 million. The financing comes from sources from the private and public sector including CTI Life Sciences Fund L.P., Qiagen N.V. and the Ontario Capital Growth Corporation through its Emerging Technologies Fund. (more…) Read more